Compare EXFY & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXFY | MGNX |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.1M | 115.8M |
| IPO Year | 2021 | 2013 |
| Metric | EXFY | MGNX |
|---|---|---|
| Price | $1.38 | $1.78 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 5 |
| Target Price | ★ $4.50 | $3.20 |
| AVG Volume (30 Days) | 446.5K | ★ 955.6K |
| Earning Date | 02-26-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $143,907,000.00 | $127,626,000.00 |
| Revenue This Year | $4.44 | N/A |
| Revenue Next Year | $0.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.71 | N/A |
| 52 Week Low | $1.30 | $0.99 |
| 52 Week High | $4.00 | $3.00 |
| Indicator | EXFY | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 45.30 | 49.06 |
| Support Level | $1.30 | $1.66 |
| Resistance Level | $1.48 | $1.97 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 52.27 | 29.58 |
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.